We explored the concomitant effect of the International Prognostic Index at the time of relapse (IPI-R) and the time from initial diagnosis to relapse (TTR) on outcome of 80 uniformly treated patients receiving BEAM conditioning followed by SCT for relapsed, chemosensitive diffuse large B-cell lymphoma. Median age at the time of transplantation was 62 years (range 26-77). Median follow-up of survivors was 31.4 months. Median overall survival (OS) from the time of transplant for patients with TTR 418 months vs p18 months was not reached and 50 months, respectively (P ¼ 0.01). Median OS for patients with IPI-R X3 was 23.3 months and not reached for patients with IPI-R o3 (P ¼ 0.01). These factors were independent in multivariate analysis with relative risk for death of 0.91 (0.80-0.99; P ¼ 0.04) for each 6-month increment in TTR and 0.63 (0.42-0.96; P ¼ 0.03) for IPI-R o3. TTR p18 months and IPI-R X3 were combined in a prognostic system where patients with none (n ¼ 32), one (n ¼ 39) or two (n ¼ 9) of these factors had median OS not reached, of 50 and 5 months, respectively (Po0.01). Patients with early, high IPI-R relapse after first-line therapy have a dismal outcome with SCT and should receive experimental therapies.
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Background Diffuse large B-cell lymphoma (DLBCL), as defined by the WHO (World Health Organization) classification, is the most common type of non-Hodgkin lymphoma (NHL) worldwide 1 and is itself a heterogeneous entity as attested by the diversity of patterns of gene expression in tumor cells 2, 3 and variability in clinical presentation and response to therapy.
Although anthracycline-based chemoimmunotherapy [4] [5] [6] with or without radiation 7 can cure over half the patients with newly diagnosed DLBCL, patients who relapse have a very small chance to achieve a durable remission with conventional doses of chemotherapy. [8] [9] [10] [11] In the setting of relapsed disease, high-dose chemotherapy followed by autologous SCT was established by the Parma trial 8 as the preferred treatment and can rescue approximately 40% of these patients. This practice was rapidly and widely adopted and now constitutes the standard of care. Changes have been incorporated along the years to make transplantation more feasible, accessible and less toxic, perhaps the most important being the use of peripheral blood instead of bone marrow as preferable source of stem cells. 12, 13 Predictors of outcomes for patients undergoing autologous hematopoietic stem cell (HSC) transplantation for aggressive relapsed NHL are only partially known. In a reanalysis of the Parma trial, including both the transplantation and the non-transplantation arms, time from initial diagnosis to relapse (TTR) was found to have a prognostic role. 14 However, its specific impact in patients undergoing transplantation has not been determined.
Multiple attempts have been made to apply the International Prognostic Index calculated at the time of relapse (IPI-R) to cohorts of patients undergoing transplantation. An adaptation of the IPI, the age-adjusted IPI (aa-IPI, excludes age and extent of extra nodal disease) has been proposed as a better prognostic system in patients undergoing transplantation, reflecting the uniformly young population included in early series. Although aa-IPI at relapse did not predict the outcome of patients undergoing transplantation in the Parma trial, 15 this finding conflicts with subsequent series where IPI-R 16, 17 or aa-IPI 18, 19 were able to predict survival after transplantation. These series, although very informative, included multiple histologies of lymphoma, broad variety of conditioning regimens (some using TBI), heterogeneous source of stem cells and often restricted inclusion to younger patients.
The present study assesses the prognostic role and independence of IPI-R and TTR in a modern, uniform and non-age-restricted cohort and introduces a simple and powerful tool to predict the outcome of patients with relapsed chemosensitive DLBC undergoing high-dose chemotherapy and autologous SCT.
Methods

Patients
Records of all consenting patients receiving an autologous SCT at Mayo Clinic, Rochester, MN, USA, between January 2001 and December 2006 for DLBCL were retrospectively reviewed. For diagnosis of DLBCL not performed at the institution, original outside pathology slides and computed tomography images had been prospectively retrieved and reanalyzed. To be included in this report, patients were required to have documented relapse after obtaining at least an unconfirmed complete response on anthracycline-based chemotherapy administered with or without rituximab and/or irradiation. In addition, included patients had to have chemosensitive relapse defined as at least a partial response to salvage chemotherapy. Patients receiving high-dose chemotherapy and autologous HSC for high-risk DLBCL in first complete response were excluded as well as patients with refractory disease and patients receiving conditioning therapy other than BCNU, etoposide, cytarabine and melphalan (BEAM). Patients with transformed lymphomas or primary central nervous system lymphomas were excluded. Age was not an exclusion criterion.
In compliance with the institutional guidelines for autologous SCT eligibility, all patients had to demonstrate appropriate cardiac function with an ejection fraction by echocardiogram 450% and no symptoms of congestive heart failure. Pulmonary function was demonstrated by a forced expired volume in the first second 450% and diffusion capacity of carbon monoxide 450% of predicted value. Patients were also required to have creatinine o2.5 Â upper normal limit, bilirubin o1.5 Â upper normal limit and Eastern Cooperative Oncology Group (ECOG) performance status o3 prior to transplant.
All included patients provided informed consent to undergo autologous SCT and allowed their clinical records to be reviewed for research purposes. The present analysis was approved by the Institutional Review Board of the Mayo Clinic.
Treatment
For all included patients, at least one attempt was made to collect G-CSF-or GM-CSF-mobilized PBSCs through daily apheresis sessions. For patients whose number of CD34 þ cells collected was considered insufficient or who never had sufficient number of circulating CD34 þ cells to justify harvesting, autologous bone marrow was collected under general anesthesia and infused alone or in addition to the peripheral blood product on day 0.
Chemotherapy doses for the conditioning regimen were calculated employing the corrected ideal body weight. In the circumstances were actual weight was lower than ideal body weight, actual weight was used. Conditioning chemotherapy consisted of BCNU 300 mg/m 2 on day À6, etoposide 200 mg/m 2 /day divided in two daily doses on days À5 to À2, cytarabine 200 mg/m 2 /day divided in two daily doses on days À5 to À2, melphalan 140 mg/m 2 on day À1. Cryopreserved HSCs were infused on day 0. Patients received GM-CSF 500 mcg/day from day þ 6 until engraftment, platelets transfusion was given for active bleeding or platelet count o10 Â 10 9 /l; packed red blood cells were transfused for symptomatic anemia or hemoglobin o8.0 g/100 ml. Patients received prophylaxis for infectious complications with acyclovir (from day À6 to day þ 30), levofloxacin (from day 0 until engraftment), fluconazole (from day 0 until engraftment) and trimethoprim-sulfamethoxazole (from day þ 30 to day þ 100). Neutrophil engraftment was defined as the first of three consecutive days of absolute neutrophil count 40.5 Â 10 9 /l and platelet engraftment as the first of three consecutive days of platelet count 450 Â 10 9 /l without platelet transfusion. Treatment-related mortality was defined as rate of death occurring before day þ 100 in the absence of recurrence of the primary disease.
Prognostic factors
Each patient was retrospectively categorized according to the IPI-R for non-Hodgkin lymphoma. Poor prognostic factors accounted for in this prognostic system are advanced stage (III or IV), elevated lactic dehydrogenase, poor performance status (ECOG 41), presence of more than one site of extra-nodal disease and advanced age (460 years). 20 Patients were considered low risk if none or one poor prognostic factor was present; low intermediate risk if two factors were present; high intermediate risk if three factors were present and high risk if more than three factors were present. To assess the effect of IPI-R on transplantation outcomes, patients with low and low intermediate risk (IPI-Ro3) and high intermediate and high risk (IPI X3) were grouped into two categories: 'low IPI-R' and 'high IPI-R', respectively.
Time to relapse was retrospectively calculated for each patient as the time between commencing the first-line anthracycline-based chemotherapy and the first clinical or radiological evidence of relapsed disease occurring after CR or unconfirmed complete response.
Statistics
Overall survival (OS), disease-free survival (DFS) and cumulative incidence of relapse (CIR) were calculated from the transplant day until the day the event (death or relapse) was documented. Deaths with no evidence of disease were considered events for OS and DFS and were censored for CIR analysis. OS and CIR curves were generated using the method of Kaplan and Meier (complement of Kaplan-Meier for CIR). Comparisons of time variables between groups (according to IPI-R or TTR) were made using log-rank analysis.
One main purpose of the study was to test the independence between TTR and IPI-R as predictors of outcome of chemosensitive DLBCL after autologous SCT. To do so, Cox proportional hazard regression analysis was performed, including IPI-R (grouped in IPI-R X3 and IPI-R o3), treated as a discrete variable, and TTR, treated as a continuous variable, age and disease status at the time of transplant (CR or non-CR). All statistical tests used a significance level of 0.05.
Results
Eighty patients met the criteria outlined in Methods and were included in the present analysis. The demographic and disease-related characteristics are delineated in Table 1 . Median age at the time of transplant was 62 years (range 26-77). The vast majority of patients received a transplant after one line of chemotherapy was given in first relapse.
Sixty-seven patients were able to collect adequate number of CD34 þ cells by apheresis and received a PBSCT. Nine patients received both PBSC and bone marrow, and four patients received bone marrow only. All patients were treated with the planned doses of the conditioning regimen (BEAM). The median number of CD34 þ cells infused was 5 Â 10 6 /kg (range 2-11.1 Â 10 6 /kg) for the patients receiving PBSC only. Neutrophil engraftment occurred after a median of 12 days (range 10-69) and platelet engraftment after 15 days (range 8-617). Four patients (5%) never reached criteria for platelet engraftment.
By July 2007, 54 (68%) patients were alive, 9 with active disease. Median follow-up of survivors was 31.4 months (range 4-74.2). There had been 26 deaths, 21 as a direct consequence of disease progression. Causes of death in the remaining five patients (three in CR) were multi-organ failure, respiratory failure, secondary malignancy (two patients) and suicide. Day þ 100 treatment-related mortality was 0%.
Effect of TTR
The median time from initiation of anthracycline-based chemotherapy to clinical or radiological evidence of relapse was 19 months (range 6-165). In univariate analysis, a longer TTR (treated as a continuous variable) was associated with longer DFS (relative risk (RR) 0.91 for each 6-month increment; 95% CI: 0.82-0.98; P ¼ 0.01) and OS (RR 0.90; 95% CI: 0.80-0.99; P ¼ 0.03) and approached significance for CIR (RR 0.93; 95% CI: 0.84-1.002; P ¼ 0.06). Median survival was 50 months for patients with TTR p18 months (therefore less than the median TTR of 19 months) and not reached (n.r.) for patients with TTR 418 months (P ¼ 0.01; Figure 1 ).
Effect of IPI-R
Distribution of patients according to IPI-R score is displayed in Table 1 . In univariate analysis, low IPI-R was associated with better OS (RR 0.61; 95% CI: 0.42-0.94; P ¼ 0.02) but not with CIR (RR 0.75; 95% CI: 0.52-1.11; P ¼ 0.15) or DFS (RR 0.74; 95% CI: 0.53-1.09; P ¼ 0.12). Median survival in the high IPI-R group was 23.3 months and nr in the low IPI-R group (P ¼ 0.02; Figure 2 ).
Multivariate analysis
To test the independence of TTR and IPI-R as determinants of OS after SCT, Cox proportional hazard regression analysis was performed including these two factors, age and disease status at the time of transplantation (CR or non-CR). Using stepwise forward selection of variables, only TTR and IPI-R were found to contribute to the final model. In the final analysis, both longer TTR (RR 0.91 for each 6-month increment; 95% CI: 0.80-0.99; P ¼ 0.04) and low IPI-R (RR 0.63 for IPI-R o3; 95% CI: 0.42-0.96; P ¼ 0.03) were associated with longer OS. The two identified prognostic factors were then integrated in a prognostic system with TTR being treated as a discrete variable for convenience (TTR p18 vs TTR 418 months). The presence of none (n ¼ 32), one (n ¼ 39) or both (n ¼ 9) poor prognostic features, TTR p18 months and IPI-R X3, defined three groups of patients with distinct CIR and OS. In fact, median time to relapse after transplant for patients with zero, one and two poor prognosis factors was n. 
Discussion
Approximately 40% of the patients diagnosed with DLBCL will eventually face relapsed or refractory disease. 5, 21 Multiple single-arm studies performed in the 1980s and early 1990s suggest that a significant proportion of patients with aggressive NHL can be cured with myeloablative chemotherapy and ABMT. 20, [22] [23] [24] [25] Such studies led the randomized phase 3 trial conducted by the Parma group demonstrating superiority of high-dose chemotherapy over conventional chemotherapy in patients with chemosensitive persistent or relapsed aggressive NHL. 8 Although no further randomized studies have been performed, the benefit of transplantation has been reinforced by several nonrandomized studies. 22, 26 Since the publication of the Parma study, several innovations have been assimilated in the practice of autologous transplantation in DLBCL. Better recognition of the histological subtypes and universal adoption of the Revised European-American Lymphoma (REAL) classification, 27 latter endorsed by the WHO 28 allowed transplant results to be reported in a per histology basis, separating DLBCL from other entities with markedly different biology and response to treatment such as mantle-cell lymphoma 29 and peripheral T-cell lymphomas. 30 Moreover, growth-factor and/or chemotherapy-mobilized PBSC (as opposed to bone marrow) have become the preferred source of stem cells due to faster engraftment and greater convenience. 12, 13 Also with the advances in supportive care and accumulation of experience, the benefit of HSC transplantation has been safely extended to elderly patients. 31 Predicting the outcome of patients undergoing autologous transplantation for DLBCL may not only properly inform patients but also help physicians to identify groups of patients with anticipated poor outcome despite transplantation and for whom innovative treatments should be developed. Furthermore, the characterization of a transplant series according to prognostic factors is crucial for future comparisons between studies and institutions' results. In addition to the analysis of the Parma trial concerning the prognostic role of aa-IPI 15 and TTR, 14 other independent series have explored similar questions. Investigators from the Memorial Sloan-Kattering Cancer Center reported the outcome of 51 patients with 'intermediategrade' primary refractory or relapsed lymphoma treated with intent to proceed to autologous transplantation (performed in 34 cases) and found that IPI-R was predictive of failure-free survival at 2.5 years. 16 The same institution later reported 98 patients with refractory or relapsed chemosensitive DLBCL (including 'transformed' cases) undergoing autologous SCT and identified aa-IPI at the time of initiation of second-line chemotherapy as a predictor of OS and DFS at 4 years. 19 Jabbour et al. 18 in a series of 40 patients with aggressive NHL undergoing autologous transplantation also identified aa-IPI as being a predictor of OS and DFS. This study, however, found that TTR did not predict outcome. By performing a retrospective analysis of patients undergoing HSC transplant for aggressive NHL over a period of 18 years, investigators from the University of Minnesota also have recently reiterated the prognostic value of IPI-R. 17 The present study confirms the prognostic value of IPI-R in a modern cohort of patients with relapsed DLBCL undergoing transplantation, demonstrates the independence of TTR and proposes a simple prognostic system incorporating IPI-R and TTR, and able to separate three groups of patients with very distinct outcomes. As opposed to previously published series, [14] [15] [16] [17] 19 the present study included exclusively DLBCL histology. All patients had relapsed chemosensitive disease, received the same non-TBI-based conditioning regimen and intended to receive PBSCT, a practice now considered standard of care. Perhaps even more important, age has not been a determinant factor at Mayo Clinic, Rochester, MN, USA, in indicating transplant for patients with relapsed DLBCL 31 and was not used as exclusion criteria in selecting cases for the current analysis. In fact the median age of patients included in this series (62 years) was at least 11 years higher than that of any of the other published series addressing the same or similar question. We found that the absence of treatment-related mortality and the excellent long-term outcome, even when compared to series treating much younger patients, support our practice of not selecting patients for autologous transplant based on age exclusively. The fact that this is the first series of its type in which the majority of patients has been previously exposed to rituximab is also of interest, given that rituximab has been shown to modify the interpretation of traditional prognostic criteria in other disease settings. 32 The present results indicate that using modern standards for autologous transplantation, patients with DLBCL relapsing with low IPI-R after 18 months of initiation of therapy have approximately 80% of chance of being alive in 5 years, assuming that the lymphoma is still chemosensitive and patients are otherwise candidates for transplant. On the opposite side, high IPI-R and short TTR identify a group of patients for whom innovative transplant and non-transplant approaches are needed. Efforts should be made to include these patients in clinical trials, perhaps testing new drugs in the relapsing setting or the use of radioimmunoconjugates as part of the conditioning regimen. [33] [34] [35] The prognostic system proposed here is practical and powerful but needs to be validated in an independent cohort. Although clinically relevant, a prognostic model constituted by IPI-R and TTR will not be perfect, in part because these markers are likely surrogates of a tumor's capacity to proliferate, migrate and resist the lethaal effects of chemotherapy. As such, they will be complemented or replaced, as more genuine biological features (such as gene expression profile) are incorporated into prognostic systems.
